RNA shot takes aim at diabetes in tiny early trial
NCT ID NCT07347080
First seen Jan 21, 2026 · Last updated Apr 30, 2026 · Updated 11 times
Summary
This early-phase study tests a single injection of CR059, a new RNA-based medicine that helps the body produce a diabetes drug (exenatide) on its own. It involves 9 Chinese adults with type 2 diabetes to check safety and how the drug works in the body. The goal is to see if this approach can control blood sugar, but it is not a cure and requires ongoing management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITINGLuoyang, Henan, 310015, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.